Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to
 ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of
 ≥ 8 points (International Prostate Symptom Score (IPSS))
Inclusion Criteria:

 -  Patients suffering from BPH symptoms

 -  Preceding treatment with a phytotherapeutic for at least 4 weeks

 -  IPSS sum score ≥ 8 points prior to treatment start with ALNA®

 -  Indication for a switch to treatment with ALNA® for a minimum period of 2 months

 Exclusion Criteria:

 -  Patients fulfilling one of the general or specific contraindications listed in the
 ALNA® Summary of Product Characteristic, particularly patients with known
 hypersensitivities against tamsulosin hydrochloride or any other ingredient of the
 product, orthostatic dysregulation or severe liver insufficiency

 -  Patients receiving ALNA® within the 4 weeks prior to the start of the present
 observational study